15.
VERVE-102: one-shot base editing to lower LDL cholesterol
Eli Lilly presented data on a single-infusion base-editing therapy targeting cholesterol biology, pointing toward durable cardiovascular-risk reduction
@afshineemrani on Backlist
1 appearance on the backlist front page in the last 30 days.